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trials for multiple sclerosis
ABSTRACT
Objective: We aimed to provide recommendations for addressing comorbidity in clinical trial
design and conduct in multiple sclerosis (MS).
Methods: We held an international workshop, informed by a systematic review of the incidence
and prevalence of comorbidity in MS and an international survey about research priorities for
studying comorbidity including their relation to clinical trials in MS.
Results: We recommend establishing age- and sex-specific incidence estimates for comorbidities
in theMS population, including those that commonly raise concern in clinical trials of immunomod-
ulatory agents; shifting phase III clinical trials of new therapies from explanatory to more prag-
matic trials; describing comorbidity status of the enrolled population in publications reporting
clinical trials; evaluating treatment response, tolerability, and safety in clinical trials according
to comorbidity status; and considering comorbidity status in the design of pharmacovigilance
strategies.
Conclusion: Our recommendations will help address knowledge gaps regarding comorbidity that
interfere with the ability to interpret safety in monitored trials and will enhance the generalizabil-
ity of findings from clinical trials to “real world” settings where the MS population commonly has
comorbid conditions. Neurology® 2016;86:1–9
GLOSSARY
MS 5 multiple sclerosis; PRECIS 5 Pragmatic–Explanatory Continuum Index Summary.
In 2005, more than 130 million Americans had one or more chronic health conditions.1 Such
findings are not restricted to North America.2 Many individuals with a chronic disease will have
another coexisting (comorbid) condition, and the likelihood of comorbidity increases with age.
Comorbidity refers to the total burden of (chronic) illness other than the specific disease of
interest.3 Multimorbidity refers to the co-occurrence of 2 or more chronic conditions in an
individual; it does not emphasize a specific index condition.4
Physical (medical) and psychiatric comorbidities are common in multiple sclerosis (MS).5
Recent reviews suggest that the most common medical comorbidities in MS are hypertension,
hyperlipidemia, and chronic lung disease while the most common psychiatric comorbidities are
depression and anxiety.5 Several studies suggest that comorbidity is associated with disability
progression, lesion accrual on MRI, lower quality of life, hospitalizations, and mortality.6–9
However, little is known about how comorbidities influence MS-related treatment, including
the decision to treat, the choice of agent, or treatment effectiveness, safety, tolerability, and
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adherence. Therefore, an international group of
investigators in MS, epidemiology, clinical tri-
als, and comorbidity met in Toronto, Canada,
March 27 and 28, 2015, under the auspices of
the International Advisory Committee on Clin-
ical Trials in Multiple Sclerosis and sponsored
by the European Committee for Treatment
and Research in Multiple Sclerosis and the
US National Multiple Sclerosis Society. This
report describes the discussions and recommen-
dations for addressing comorbidity in the con-
text of clinical trial design and conduct in MS.
We considered the effect of comorbidity on
treatment in MS, eligibility for clinical trials,
safety monitoring, and ethical issues.
EFFECT OF COMORBIDITY ON TREATMENT OF
MS Literature regarding the effect of comorbidity on
treatment of MS is limited. Findings in other chronic
diseases suggest that comorbidity may affect multiple
aspects of treatment. First, comorbidity may impede
care. Individuals affected by multimorbidity report
multiple barriers to self-care, including the
compound effects of medications, difficulties in
coordinating multiple medications, the total burden
of medications, and financial challenges.10 Second,
comorbidity may affect the frequency or intensity of
treatment of coexisting conditions.11–14 Third,
comorbidity may affect persistence or adherence
(defined in Ref. 15) to treatment, further reducing
the benefits of therapies, which are only partially
effective. For example, depressed individuals with
diabetes are 1.5-fold less likely to persist with
pharmacotherapy for diabetes after 12 months of
follow-up than nondepressed individuals.16
Although the effect of comorbidity on persistence
with MS disease-modifying therapies is unknown,
depression is associated with reduced adherence to
disease-modifying therapy (odds ratio 0.55; 0.42–
0.74).17 Findings on whether adherence improves
after treatment of depression are inconsistent.17,18
Fourth, comorbidity may affect the effectiveness,
safety, and tolerability of treatment, although
evidence for these issues is limited in MS. In a
secondary analysis of longitudinal data from a
randomized controlled trial of a teleconference-
delivered fatigue management intervention for MS,
comorbid diabetes or arthritis modified the response
to the intervention. Individuals with diabetes
improved more slowly after intervention than those
without diabetes, while individuals with arthritis
improved more rapidly than those without arthritis
but they had difficulty sustaining improvements.19
Finally, comorbidity may increase the risk of drug–
drug and drug–disease interactions.
COMORBIDITY AND ELIGIBILITY FOR CLINICAL
TRIALS Individuals with comorbidities frequently are
underrepresented in clinical trials.20 Therefore, trial
findings may not apply to a typical clinic population
with comorbidities. Boyd et al.20 reviewed clinical trials
identified using Cochrane reviews for diabetes, heart
failure, chronic obstructive pulmonary disease, and
stroke. These trials frequently excluded individuals
with comorbidities, ranging from 0% to 44% of dia-
betes trials, 0% to 42% of heart failure trials, 0% to
55% of chronic obstructive pulmonary disease trials,
and 0% to 39% of stroke trials. Moreover, only 43.5%
(70/161) of the trials reported the prevalence of any
comorbidity among participants. Information regard-
ing the definition or ascertainment of comorbidity was
limited. Only 3.1% (5/161) of trials used comorbidity
as a subgroup variable. A review of randomized trials
published in the 5 highest-impact general medical
journals and specialized journals that focused on the
most prevalent chronic conditions found that
multimorbidity affected participant eligibility in 95%
of trials.21 Individuals with multimorbidity were
excluded in 63% of the trials examined; this did not
change from 1995 to 2010. Only 2.1% of trials
explicitly included individuals with multimorbidity.
A systematic review of 26 trials or prospective
observational studies in cardiovascular disease focused
on comorbidity measurement.22 The comorbidities
assessed varied across studies and were assessed using
varied data sources with 35% not reporting the data
source.
The situation is similar in MS where most phar-
macologic trials exclude individuals with severe co-
morbidities or substance use disorders.23–26 We
reviewed the published results of 9 sentinel placebo-
controlled trials of disease-modifying therapies
approved for MS in the United States (table 1).23–31
Five of 9 trials (55.6%) excluded individuals with
various comorbidities. In 4 of those 5 trials, the
description of the exclusions for comorbidities was
vague,25,29–31 making it unclear how they were oper-
ationalized. Uniformly, the way in which comorbid-
ity was assessed for the purposes of eligibility was not
reported. None of the trials described the comorbid-
ity status of participants at enrollment. Furthermore,
none considered the presence of comorbidity as a
subgroup variable for a priori or post hoc analyses.
Although we did not review all clinical trials of
nonpharmacologic interventions for managing symp-
toms of MS, an ongoing systematic review of comor-
bidity measurement in randomized trials of
rehabilitation interventions suggests that comorbid-
ities are only considered in relation to exclusion crite-
ria and are rarely reported when participant
characteristics are described (M. Finlayson, personal
communication, 2015). For example, Oken et al.32
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randomized patients with MS to a weekly yoga class,
weekly exercise class using a stationary bicycle, or a
waiting-list control group. Participants with insulin-
dependent diabetes; symptomatic lung disease;
uncontrolled hypertension; liver or kidney failure;
alcoholism/drug abuse; symptoms or signs of conges-
tive heart failure, ischemic heart disease, or sympto-
matic valvular disease; or corrected visual acuity worse
than 20/50 binocularly were excluded. A controlled
trial of physiotherapy as intervention to improve
mobility in MS excluded individuals with other major
general medical or surgical disorders.33
While exclusion of participants with comorbidities
is intended to ensure participant safety, the conse-
quence is that we lack knowledge about the safety,
tolerability, and efficacy of the studied regimens in
persons with MS who have common comorbidities.
Limited data suggest that safety and tolerability of
disease-modifying therapies are affected by comor-
bidity. An observational study found that individu-
als with migraine have more difficulty tolerating
interferon-b because of worsening headache pro-
files.34 The risk of fingolimod-associated macular
edema is higher among individuals with comorbid
diabetes.35 These issues are particularly important
for future trials in progressive MS, in which the target
population is likely to be older and, therefore, more
likely to have comorbidity. Excluding individuals
with comorbidities in these trials slows accrual and
produces a study population that is even more diver-
gent from clinical populations than trials conducted
in relapsing-remitting MS.
EXPLANATORYVSPRAGMATICTRIALS Randomized
clinical trials can be classified as explanatory or prag-
matic (table 2).36 Explanatory trials test the efficacy of
an intervention, that is, the effects under ideal con-
ditions. An effort is made to enhance the internal
validity of the trial by achieving a more homogeneous
study population with well-specified inclusion and
exclusion criteria, and by controlling all aspects of
the intervention and comparator. In contrast,
pragmatic trials test the effectiveness of an
intervention, that is, the effects in real-world clinical
settings where populations are more heterogeneous
and differ from those in explanatory trials.
Therefore, pragmatic trials produce findings that are
potentially more generalizable and applicable to
clinical practice. Clinical trials in MS to date largely
have been explanatory in nature.
Although this classification suggests trials fall into
distinct groups, explanatory and pragmatic trials
really exist on a continuum, and several aspects or do-
mains of a trial’s design may influence where it falls in
the continuum.37 These may include eligibility crite-
ria, the flexibility of the experimental and comparison
interventions, required investigator expertise, choice
of outcomes, intensity of follow-up and ascertain-
ment of outcomes, and measures to ensure and assess
adherence to the interventions by the participants and
practitioners.37 The Pragmatic–Explanatory Contin-
uum Index Summary (PRECIS) tool and its subse-
quent revision (PRECIS-2)38,39 were developed to
assist trialists in considering these factors when
designing their trials with the goal of matching
Table 1 Consideration of comorbidities in phase III placebo-controlled sentinel trials of disease-modifying therapies in MS
Author Year Trial name Agent
Age
range, y Comorbidities excluded
Comorbidities
reported as
characteristics of
study population
Comorbidities reported as
adverse events
IFNB23 1993 Interferon-
b-1b
18–50 None stated None Cardiac arrhythmia
Johnson24 1995 Glatiramer
acetate
18–45 IDDM, positive HIV or HTLV-I serology,
evidence of Lyme disease, required use
of NSAIDs or aspirin during trial
None
PRISMS27 1998 PRISMS Interferon-
b-1a
Not
specified
None stated None Depression
Jacobs25 1996 MSCRG Interferon-
b-1a
18–55 Conditions other than MS compromising
organ function
None Depression
Hartung26 2002 MIMS Mitoxantrone 18–55 None stated None Arrhythmia
Polman28 2006 AFFIRM Natalizumab 18–50 None stated None Melanoma
Kappos29 2010 FREEDOMS Fingolimod 18–55 Diabetes, immune suppression, clinically
significant systemic disease
None Neoplasms, macular edema,
hypertension, AV block,
hypercholesterolemia,
depression
O’Connor30 2011 TEMSO Teriflunomide 18–55 Other systemic diseases None Hypertension
Gold31 2012 DEFINE Dimethyl
fumarate
18–55 Another major disease that would
preclude participation in a clinical trial
None Neoplasms (renal failure)
Abbreviations: AV 5 atrioventricular; HTLV-I 5 human T-lymphotropic virus 1; IDDM 5 insulin dependent diabetes mellitus; MS 5 multiple sclerosis;
NSAID 5 nonsteroidal anti-inflammatory drug.
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designs to the intended uses of the trial results. The
tool could also be used to evaluate existing trials (for a
more detailed description of PRECIS-2, see appendix
e-1 on the Neurology® Web site at Neurology.org).
Pragmatic trials face challenges. Because the inter-
vention(s) is not as tightly controlled, it may not be
as well delivered, reducing its benefit. Increased heter-
ogeneity and the dilution of the intervention’s effect
require larger sample sizes (discussed further in Ref.
40) and longer follow-up time, increasing costs and
the risk of attrition. Although a pragmatic trial may
be performed in multiple clinical settings, we cannot
assume that the findings from one clinical setting trans-
late to other clinical settings. Nonetheless, relaxing cri-
teria regarding age and comorbidity status could enroll
a population more similar to that seen in clinic settings.
COMORBIDITY AND SAFETY MONITORING IN
CLINICAL TRIALS All clinical trials need safety
monitoring. Typically, large randomized, multisite
studies such as those used to evaluate disease-
modifying therapies establish a Data Safety
Monitoring Committee, which reviews trial conduct
and accumulating data and advises the study
sponsor regarding the ongoing safety of the
trial participants. When participants experience
treatment emergent adverse events including
comorbidities such as hypertension, the Data Safety
Monitoring Committee must decide whether the
observed events are occurring at a rate greater than
expected and whether they are treatment-related
(i.e., a true safety signal) or not. Understanding
how adverse events may affect differentially those
with comorbidity is also important.
For common adverse events, the observed event
rates can simply be compared between intervention
groups, that is, using data internal to the trial. How-
ever, for rare (i.e., with a low event rate), serious
adverse events such as cancers, the use of external
comparators is needed. Such assessments require a
good understanding of the expected age- and sex-
specific incidence of comorbidities in the (untreated)
MS population as these may differ from the rates re-
ported for the general population. However, a recent
systematic review identified very few studies evaluat-
ing the incidence of comorbidity in MS, with even
fewer being population-based.5 The most commonly
studied conditions were cancer and epilepsy; how-
ever, the time period over which incidence was being
studied was often unclear, the definition of the con-
ditions varied across studies, and age- and sex-specific
estimates were not generally reported. Thus, the
information necessary to assess the significance of rare
but clinically important adverse events is largely
lacking.
Often it is not until a drug is released to the mar-
ket that it is used in a significant number (if any) of
individuals with comorbidities, and this is when
adverse effects specific to individuals with comorbid-
ity may be detected. However, postapproval, safety is
not monitored as systematically at the individual or
group level as in clinical trials. Although the strategies
used for postmarketing surveillance vary somewhat
across nations,41 the challenges faced are similar. Post-
marketing surveillance may involve one or more com-
ponents including passive reporting of adverse drug
reactions, active pharmacovigilance, phase IV studies,
and the use of research networks to evaluate specific
Table 2 Comparison of explanatory and pragmatic clinical trials
Explanatory Pragmatic
Test efficacy: Does this intervention work under ideal
conditions?
Test effectiveness: Does this intervention work under usual
conditions?
High internal validity at possible expense of external validity Improved external validity
Largely phase II–III Largely phase IV
Smaller sample size Larger sample size (to increase power to detect small effects)
Controlled environment Full spectrum of routine clinical settings
Emphasize homogeneity of population and intervention, e.g. Emphasize heterogeneity of population and intervention, e.g.
Restrictive inclusion/exclusion criteria All participants enrolled regardless of expected risk,
comorbidities, adherence
Instructions about applying intervention strict for all
components
Instructions about applying intervention flexible
Select highly experienced practitioners Include practitioners with range of skills
Outcomes focus on measurable symptoms or markers Spectrum of outcomes, largely patient-centered
Shorter but intense follow-up Longer, less intense follow-up
Adherence of participants and practitioners carefully assessed Adherence is assessed minimally or not at all
Intention-to-treat analysis, possibly supplemented by
per-protocol analysis
All patients
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adverse events of interest. Passive reporting systems
underreport adverse drug reactions by as much as
98% as compared to systematic monitoring, and
phase IV studies may not be completed as re-
quested.41 Specific efforts are required to assess the
safety of new therapies in individuals with MS and
comorbidities in the postmarketing phase.
ETHICAL ISSUES Consideration of whether to
include or exclude participants with comorbidity in
a clinical trial illustrates a potential conflict in ethical
principles inherent in clinical trials. Because the life-
time prevalence of comorbidity in patients with MS
is substantial, this issue is frequently encountered in
MS trials. Expanding the age of enrolled participants
and including those with comorbidities are ways to
make the study population more typical. However,
such individuals may have decreased likelihood of
benefiting (i.e., violation of the ethical principle of
beneficence) and an elevated risk of adverse effects
(i.e., violation of the principle of nonmaleficence).
There also may be concern that inclusion of partici-
pants with comorbidity may complicate interpreta-
tion of the trial if, for example, they adhere less well
to assigned treatment or differentially discontinue
treatment or trial participation prematurely.
These considerations are potentially in conflict
with the principle of autonomy that states that unless
the safety concerns are more than hypothetical,
informed patients should have the opportunity to
participate. Moreover, the external validity (generaliz-
ability) of the study is reduced if the trial population
does not represent the clinical population in whom
the therapy will be used. From an ethical perspective,
the principle of justice suggests that particular indi-
viduals should not bear a disproportionate burden
of research participation, nor should they be unfairly
excluded from the potential benefits of participation.
Thus, excluding individuals with MS from clinical
trials solely on the basis of age or comorbidity status
requires careful consideration of the reasons and
ramifications.
RECOMMENDATIONS The workshop produced
several recommendations to address knowledge gaps
regarding the incidence of comorbidity that may
interfere with the ability to assess safety in monitored
trials, and the limited generalizability of clinical trials
to clinical settings where the MS population com-
monly has comorbid conditions. These are described
generally below and summarized in table 3 in more
detail for the most common comorbidity, psychiatric
comorbidity.
Establish age- and sex-specific incidence estimates for
comorbidities in the MS population, including those that
commonly raise concern in clinical trials of MS disease-
modifying therapies. Comorbidities prioritized for
future incidence studies were depression, anxiety,
autoimmune disease, diabetes, cancer, hypertension,
and migraine, based on several considerations. First,
they may affect clinician-assessed, patient-reported,
and imaging outcomes in MS, and health care
utilization.6–9,42 Second, they may affect adherence
to treatment.17 Third, they may affect the frequency
or severity of adverse events.35 Fourth, they may be
Table 3 Addressing psychiatric comorbidity in clinical trials for multiple sclerosis
Issues and strategies
1. Establish age- and sex-specific incidence estimates for depression and anxiety
2. For all clinical trial participants, report the severity of depression and anxiety symptoms using a validated tool and report histories
of clinician-diagnosed depression and anxiety at baseline and at the end of the clinical trial
3. Obtain a preliminary assessment of the safety of the intervention of interest in persons with comorbid depression and anxiety
e.g., In phase II clinical trials, evaluate whether the intervention of interest worsens depression/anxiety symptoms using a
validated tool (i.e., make this one of the relevant safety signals)
4. Based on phase II trials, consider inclusion of persons with depression and anxiety in phase III trials
e.g., If no safety concerns in phase II trials, allow inclusion of such individuals in phase III clinical trials unless the individual is
suicidal or so mentally ill that participation is deemed to place the person at significant risk per the health care providers most
responsible for managing their mental health
5. Ensure appropriate access to mental health care during the trial as needed
6. Monitor adherence of study participants to the intervention and evaluate whether this differs by psychiatric comorbidity status
7. Evaluate treatment response, tolerability, and safety according to psychiatric comorbidity status, as defined based on the
lifetime history of psychiatric comorbidity and severity of depression and/or anxiety at enrollment
8. If sample size is thought to be a concern because of the inclusion of participants with depression or anxiety who may have
heterogeneous responses or may be less likely to adhere to the intervention, investigators could set a threshold for the
proportion of depressed/anxious persons who could be enrolled in the trial, as higher proportions of persons with comorbidities
that may contribute to heterogeneity will increase required sample sizes40
9. Ensure that phase IV studies enroll persons with multiple sclerosis who are depressed or anxious and evaluate whether their risk
of adverse events differs from that reported in phase III trials. The use of concomitant medications should be considered in these
analyses
Neurology 86 April 12, 2016 5
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
identified as adverse events in clinical trials; cancer
and autoimmune disease were of particular interest
in this regard.43,44 Discussants also noted the
importance of considering health behaviors such as
smoking and obesity, as they are associated with the
risk of developing comorbidities and may have
independent effects on efficacy and safety.
Shift phase III clinical trials of new therapies in MS along
the continuum from explanatory to more pragmatic
trials. Specifically, we propose changes to eligibility
criteria for clinical trials of pharmacologic and non-
pharmacologic therapies. First, relax age restrictions.
Second, consider relaxing restrictions on the inclusion
of individuals with comorbidity. This has been feasi-
ble in other fields (table 4). Such decisions are a trade-
off between homogeneity of the population and the
strength of the signal being sought, safety, and gen-
eralizability of the findings to clinical practice. We
suggest that, in the absence of strong a priori safety
concerns, individuals with the most common comor-
bidities in the MS population,5 including depression,
anxiety, hypertension, hyperlipidemia, and chronic
lung disease, be considered for inclusion in trials.
Furthermore, individuals with a history of cancer
should also be considered as potential participants
in some settings. These changes will be particularly
important in trials in progressive MS, as these indi-
viduals will be older and will have a greater burden of
comorbidity. These changes will require larger trials.
The comorbidity status of enrolled clinical trial
populations should be clearly and consistently
described. The description of clinical trial populations
at baseline should include the prevalence of common
comorbidities and whether they were currently trea-
ted (concomitant medications). These characteristics
should also be updated and reported for the trial pop-
ulation as of the last study visit. Also, blood pressure,
body mass index, waist–hip ratio, and current symp-
toms of depression and anxiety should be reported.
To facilitate comparison of findings across clinical
trials, we propose that, at a minimum, the presence
or absence of the following diagnoses be reported:
depression, anxiety, hypertension, hyperlipidemia,
chronic lung disease (including asthma and chronic
obstructive pulmonary disease), diabetes, autoim-
mune thyroid disease, migraine, and prior cancers.
Ideally, these conditions would be verified by review
of medical records and would not be based solely on
self-report at the time of trial enrollment. For the
measurement of current symptoms of depression
and anxiety, it would be helpful if a single tool was
used consistently in trials. Although several choices
exist for depression, less work has validated scales for
anxiety.50,51 Further evaluation of the responsiveness
of available tools in the MS population would assist in
identifying the best instrument. A systematic review
of the psychometric properties of depression scales is
ongoing and may provide guidance.52
Evaluate treatment response, tolerability, and safety in
clinical trials according to comorbidity status and health
behavior status. Based on observational studies show-
ing that comorbidity and health behaviors affect
clinician-assessed, patient-reported, and imaging
outcomes in MS,7–10,42 it is likely that efficacy,
safety, and tolerability differ by comorbidity status.
This issue needs to be assessed to ensure that
individuals with MS are not offered ineffective
treatments while incurring risks. The initial focus of
such subgroup analyses should focus on common,
readily measured comorbidities such as hypertension,
diabetes, smoking status, and obesity.
Comorbidity status should be considered in the design of
postmarketing pharmacovigilance strategies. Phase IV
studies should aim to enroll individuals with comor-
bidities and evaluate whether their risk of adverse
events differs from that reported in phase III trials.
The use of concomitant medications should be con-
sidered in these analyses. Research networks with
access to large databases should be used to conduct
studies to specifically assess the risk of significant
Table 4 Examples of pragmatic trials with relaxed eligibility criteria for age or comorbidity
Trial (name
or lead
author) Question Eligibility criteria regarding age and comorbidity Trial registration
Price45 Are leukotriene antagonists equivalent to inhaled
glucocorticoids as first-line management of asthma?
Age 12–80 y; excluded acute or chronic pulmonary
processes; other comorbidities allowed
Controlled clinical trials
no. ISRCTN99132811
WHICH?
trial46,47
Is multidisciplinary management of patients with CHF
post–acute hospitalization delivered in a patient’s own
home superior to care delivered via a specialist CHF
outpatient clinic?
Age $18 y; excluded persons with a terminal condition
likely to result in death or hospitalization within 12 mo
Australian New Zealand
clinical trials registry no.
12607000069459
DRESS
study48,49
Is TNF blocker dose reduction noninferior to usual care with
regard to persistent disease flare in rheumatoid arthritis?
Only exclude persons with comorbidity if it also requires
treatment with anti-TNF agents (e.g., Crohn disease) or
when it is expected that the outcome cannot be measured
(e.g., short life expectancy, planned major surgery)
Dutch trial register
NTR3216
Abbreviations: CHF 5 chronic heart failure; TNF 5 tumor necrosis factor.
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adverse events in individuals with comorbidities who
use new therapies. The use of registries of all individ-
uals using a novel therapy also may be helpful.
CONCLUSION Comorbidity is common in the MS
population and affects safety and benefit of pharma-
cologic and nonpharmacologic therapies, including
those being tested in clinical trials. The eligibility cri-
teria used in trials that restrict participants based on
comorbidities are a tradeoff between homogeneity
of the population and the strength of the signal being
sought, safety, and generalizability of the findings.
The proposed recommendations are intended to
allow clinical trials to better inform use of MS thera-
pies in clinical practice.
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